Trevor Feinstein, MD
Hematology & Oncology · Fayetteville, GANPI 1457545709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $213,331 of the $340,687 with a category attached, or 62.6%. 56 manufacturers reported payments, led by Sanofi at 51.6% of the total. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $709.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$176K
- AstraZeneca$62K
- Sobi, Inc$34K
- Recordati_rare_diseases_inc.$9K
- Pfizer$9K
- Daiichi Sankyo Inc.$8K
- plus $43K from 50 others
Across 195 payments — averaging $9950.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1M
- Astellas Pharma Global Development$292K
- Astrazeneca UK Limited$163K
- Janssen Research & Development, LLC$106K
- Novocure Inc.$84K
- Bristol Myers Squibb$43K
- plus $215K from 10 others
What the payments were for
- Consulting fees$83,73225%
- Speaking & faculty fees$213,33163%
- Travel & lodging$31,9529%
- Food & beverage$11,5873%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$340,687 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bexarotene | 14 | $1,172,754 |
| RevlimidLenalidomide | 56 | $1,016,625 |
| KisqaliRibociclib Succinate | 55 | $794,611 |
| ErleadaApalutamide | 50 | $742,440 |
| PomalystPomalidomide | 22 | $496,976 |
| OnuregAzacitidine | 12 | $307,267 |
| BrukinsaZanubrutinib | 17 | $247,236 |
| InlytaAxitinib | 12 | $231,266 |
| VenclextaVenetoclax | 23 | $221,890 |
| IbrancePalbociclib | 13 | $201,963 |
| VerzenioAbemaciclib | 13 | $200,584 |
| EliquisApixaban | 188 | $165,351 |
| Abiraterone Acetate | 65 | $161,717 |
| RozlytrekEntrectinib | 11 | $155,863 |
| Lupron DepotLeuprolide Acetate | 26 | $154,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,095 | $1,016,62556 claims |
| NovartisKisqali, Tasigna | $3,079 | $922,06468 claims |
| Johnson & JohnsonErleada, Xarelto | $5,444 | $826,939143 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $39 | $804,24334 claims |
| PfizerInlyta, Ibrance, Eliquis | $8,720 | $598,580213 claims |
| AbbVieVenclexta, Lupron Depot | $383 | $376,15349 claims |
| Beigene USA, Inc.Brukinsa | $26 | $247,23617 claims |
| Lilly USA, LLCVerzenio | $1,800 | $200,58413 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,408 | $161,71765 claims |
| Genentech USA, Inc.Rozlytrek | $181 | $155,86311 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $71 | $136,51012 claims |
| AstraZenecaCalquence | $61,870 | $114,67314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Fayetteville
- Shyam KhanwaniFayetteville$35K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.